ANTARES PHARMA, INC. (NASDAQ:ATRS) Files An 8-K Financial Statements and ExhibitsItem 9.01
(d) Exhibits.
|
Exhibit No. |
Description |
| 1.1 | Sales Agreement, dated August11, 2017, by and between Antares Pharma, Inc. and Cowen and Company, LLC |
| 5.1 | Opinion of Morgan, Lewis& Bockius LLP |
| 23.1 | Consent of Morgan, Lewis& Bockius LLP (included in Exhibit 5.1) |
ANTARES PHARMA, INC. ExhibitEX-1.1 2 d440694dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version ANTARES PHARMA,…To view the full exhibit click here
About ANTARES PHARMA, INC. (NASDAQ:ATRS)
Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.
